Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results
March 06, 2020 13:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 06, 2020 12:33 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Participate in Upcoming Investor Conferences
November 13, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results
November 06, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
First MANIFEST data showing signs of CPI-0610 clinical activity in JAK-inhibitor-naïve myelofibrosis patients Data showing signs of continuing activity in ruxolitinib-refractory or -intolerant...
Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise
September 24, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals to Participate in Two Investor Conferences
August 21, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results
August 07, 2019 16:05 ET
|
Constellation Pharmaceuticals , Inc.
Data presented at ASCO and EHA suggest potential disease-modifying activity of CPI-0610 across the spectrum of myelofibrosis (MF) parameters, with multiple potential pathways for approval The EZH2...
Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209
June 12, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Jacob Stuckey, Senior Scientist at Constellation Pharmaceuticals,...
Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting
May 20, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Patricia Keller, Senior Scientist at Constellation...
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results
March 14, 2019 17:24 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...